JAMES VANRIESSEN: Open Payments
NPI 1184721219 · SPRINGFIELD, MO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,851 in 99 payments from 19 companies in 2025. Trend: 2023 $2,413 · 2024 $1,955 · 2025 $1,851
Food & beverage: $1,851
| Company | Payments | Amount |
|---|---|---|
| Abbott Laboratories | 11 | $521 |
| AstraZeneca Pharmaceuticals LP | 9 | $251 |
| ABBVIE INC. | 25 | $247 |
| Novo Nordisk Inc | 12 | $162 |
| PFIZER INC. | 13 | $154 |
| GlaxoSmithKline, LLC. | 5 | $83 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 4 | $67 |
| Lilly USA, LLC | 4 | $61 |
| Exact Sciences Corporation | 3 | $50 |
| Axsome Therapeutics, Inc. | 2 | $46 |
Products named: FREESTYLE LIBRE, FARXIGA, VRAYLAR, NURTEC ODT, UBRELVY, Wegovy, XIFAXAN, QULIPTA.
Industry payments across MO — which companies pay providers there.
